Daisuke Doi

Daisuke Doi

Auto-generated profile, based on publicly available information

Daisuke Doi

Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
DDDaisuke Doi
Daisuke Doi
HMHiroaki Magotani
Hiroaki Magotani
TKTetsuhiro Kikuchi
Tetsuhiro Kikuchi
MIMegumi Ikeda
Megumi Ikeda
SHSatoe Hiramatsu
Satoe Hiramatsu
JTJun Takahashi
Jun Takahashi
Induced pluripotent stem cell (iPSC)-derived dopaminergic (DA) neurons are an expected source for cell-based therapies for Parkinson’s disease (PD). The regulatory criteria for the clinical application of these therapies, however, have not been established. Here we show the results of our pre-clinical study, in which we evaluate the safety and efficacy of dopaminergic progenitors (DAPs) derived from a clinical-grade human iPSC line. We confirm the characteristics of DAPs by in vitro analyses. We also verify that the DAP population include no residual undifferentiated iPSCs or early neural stem cells and have no genetic aberration in cancer-related genes. Furthermore, in vivo studies using immunodeficient mice reveal no tumorigenicity or toxicity of the cells. When the DAPs are transplanted into the striatum of 6-OHDA-lesioned rats, the animals show behavioral improvement. Based on these results, we started a clinical trial to treat PD patients in 2018.

16 April 2025 in Nature
Verified
Journal Article
Open access
PDF file
NSNobukatsu Sawamoto
Nobukatsu Sawamoto
DDDaisuke Doi
Daisuke Doi
ENEtsuro Nakanishi
Etsuro Nakanishi
MSMasanori Sawamura
Masanori Sawamura
TKTakayuki Kikuchi
Takayuki Kikuchi
JTJun Takahashi
Jun Takahashi
Parkinson’s disease is caused by the loss of dopamine neurons, causing motor symptoms. Initial cell therapies using fetal tissues showed promise but had complications and ethical concerns1,2,3,4,5. Pluripotent stem (PS) cells emerged as a promising alternative for developing safe and effective treatments6. In this phase I/II trial at Kyoto University Hospital, seven patients (ages 50–69) received bilateral transplantation of dopaminergic progenitors derived from induced PS (iPS) cells. Primary outcomes focused on safety and adverse events, while secondary outcomes assessed motor symptom changes and dopamine production for 24 months. There were no serious adverse events, with 73 mild to moderate events. Patients’ anti-parkinsonian medication doses were maintained unless therapeutic adjustments were required, resulting in increased dyskinesia. Magnetic resonance imaging showed no graft overgrowth. Among six patients subjected to efficacy evaluation, four showed improvements in the Movement Disorder Society Unified Parkinson’s Disease Rating Scale part III OFF score, and five showed improvements in the ON scores. The average changes of all six patients were 9.5 (20.4%) and 4.3 points (35.7%) for the OFF and ON scores, respectively. Hoehn–Yahr stages improved in four patients. Fluorine-18-l-dihydroxyphenylalanine (18F-DOPA) influx rate constant (Ki) values in the putamen increased by 44.7%, with higher increases in the high-dose group. Other measures showed minimal changes. This trial (jRCT2090220384) demonstrated that allogeneic iPS-cell-derived dopaminergic progenitors survived, produced dopamine and did not form tumours, therefore suggesting safety and potential clinical benefits for Parkinson’s disease.

24 December 2021 in Journal of Parkinson’s Disease
Verified
Journal Article
Open access
PDF file
SHSatoe Hiramatsu
Satoe Hiramatsu
AMAsuka Morizane
Asuka Morizane
TKTetsuhiro Kikuchi
Tetsuhiro Kikuchi
DDDaisuke Doi
Daisuke Doi
KYKenji Yoshida
Kenji Yoshida
JTJun Takahashi
Jun Takahashi
Background: Pluripotent stem cell (PSC)-derived dopaminergic (DA) neurons are an expected source of cell therapy for Parkinson’s disease. The transplantation of cell aggregates or neurospheres, instead of a single cell suspension has several advantages, such as keeping the 3D structure of the donor cells and ease of handling. For this PSC-based therapy to become a widely available treatment, cryopreservation of the final product is critical in the manufacturing process. However, cryopreserving cell aggregates is more complicated than cryopreserving single cell suspensions. Previous studies showed poor survival of the DA neurons after the transplantation of cryopreserved fetal ventral-mesencephalic tissues. Objective: To achieve the cryopreservation of induced pluripotent stem cell (iPSC)-derived DA neurospheres toward clinical application. Methods: We cryopreserved iPSC-derived DA neurospheres in various clinically applicable cryopreservation media and freezing protocols and assessed viability and neurite extension. We evaluated the population and neuronal function of cryopreserved cells by the selected method in vitro. We also injected the cells into 6-hydroxydopamine (6-OHDA) lesioned rats, and assessed their survival, maturation and function in vivo. Results: The iPSC-derived DA neurospheres cryopreserved by Proton Freezer in the cryopreservation medium Bambanker hRM (BBK) showed favorable viability after thawing and had equivalent expression of DA-specific markers, dopamine secretion, and electrophysiological activity as fresh spheres. When transplanted into 6-OHDA-lesioned rats, the cryopreserved cells survived and differentiated into mature DA neurons, resulting in improved abnormal rotational behavior. Conclusion: These results show that the combination of BBK and Proton Freezer is suitable for the cryopreservation of iPSC-derived DA neurospheres.

1 January 2010 in Journal of Nippon Medical School
Verified
Journal Article
Open access
PDF file
RKRyuhei Kurashina
Ryuhei Kurashina
HSHiromi Shimada
Hiromi Shimada
TMTakashi Matsushima
Takashi Matsushima
DDDaisuke Doi
Daisuke Doi
HAHirobumi Asakura
Hirobumi Asakura
TTToshiyuki Takeshita
Toshiyuki Takeshita
Few cases of clostridial gas gangrene associated with uterine malignancy have been reported. We report on a 46-year-old woman with clostridial sepsis. On the day of admission due to severe abdominal pain, peritonitis was diagnosed, and computed tomography showed free air in the abdomen. At emergency laparotomy, perforation of the necrotic uterine wall was observed. During hysterectomy, septic shock developed, and life-saving therapy was performed in the intensive care unit after surgery. Pathological examination of the necrotic uterine wall showed grade III endometrial adenocarcinoma of the uterine endometrium (International Federation of Gynecology and Obstetrics stage IIIa) with gas gangrene due to Clostridium perfringens. This report aims to alert gynecologists to the possibility that clostridial gas gangrene of the uterus can occur in patients with peritonitis and intra-abdominal free air. Early recognition and aggressive therapy can save patients' lives.

25 March 2009 in Gynecologic and Obstetric Investigation
Verified
Journal Article
Closed access
HAHirobumi Asakura
Hirobumi Asakura
TFTakehiko Fukami
Takehiko Fukami
RKRyuhei Kurashina
Ryuhei Kurashina
NTNaoko Tateyama
Naoko Tateyama
DDDaisuke Doi
Daisuke Doi
TTToshiyuki Takeshita
Toshiyuki Takeshita
Background/Aims: Absent cervical gland area (CGA) has been considered a predictor of preterm delivery (PTD) for women at low risk. Predictive efficacy was analyzed in women at high risk for PTD and compared with cervical length (CL) <20 mm and fetal fibronectin (fFN) in cervicovaginal secretions. Methods: Case notes were reviewed for 108 subjects with gestation of 22–33 weeks who had been admitted to hospital with threatened PTD. The uterine cervix was observed by vaginal sonography and fFN was sampled on admission. Relationships between findings and outcome of PTD at <34 weeks’ gestation were analyzed. Results: Delivery at <34 weeks’ gestation occurred in 14.8% of patients. Absent CGA (68.8%), short CL (75.0%), short CL without CGA (62.5%) and positive fFN (62.5%) were more frequent in these patients than in patients undelivered at <34 weeks’ gestation (p < 0.05). Logistic regression analysis identified positive fFN and short CL with absent CGA as independent predictors for PTD (p < 0.0001). The mean interval from admission to delivery was 2.9 weeks in cases with fFN and both sonographic findings, compared to 9.3 weeks in cases with fFN but both sonographic finding (p = 0.0005). Conclusion: Short CL with absent CGA represents an independent predictor for PTD, as does fFN.

1 January 2003 in Journal of Nippon Medical School
Verified
Journal Article
Open access
PDF file
DDDaisuke Doi
Daisuke Doi
YOYujiro Ota
Yujiro Ota
HKHideki Konishi
Hideki Konishi
KYKoichi Yoneyama
Koichi Yoneyama
TATsutomu Araki
Tsutomu Araki
Objectives: Combination chemotherapy consisting of paclitaxel and carboplatin has recently started to be given as the regimen of first choice for epithelial ovarian cancer. One of its side effects, however, is neurotoxicity, and this neurotoxicity has been reported to be the dose-limiting factor. Since it is necessary to measure the severity of the neurotoxicity objectively and quantitatively, we evaluated it on the basis of current perception threshold (CPT) values, which is easy and non-invasive. Method: Sixteen patients with epithelial ovarian cancer were given paclitaxel (175 mg/m2, 3 hours) and carboplatin (area under the curve of 5) every three weeks, and the CPT values were measured at two sites on the day before and several times after administration. Results: All patients exhibited mild neurotoxicity, but it was never so severe that chemotherapy could not be continued. The CPT values peaked on day 4 during one course of chemotherapy, but decreased thereafter and returned almost to the baseline by three weeks, in the same way as the patients' complaints. The CPT values decreased with the number of courses, and patients' complaints gradually increased. The CPT values increased more in the cases previously treated with cisplatin than in the other cases. These changes were seen at 2,000 Hz, which generally corresponds to large, myelinated nerves. Conclusion: There were correlations between the changes in the patients' CPT values and their degree of neurotoxicity. We expect to be able to predict severe neurotoxicity and evaluate the effect of drug therapy for neurotoxicity by measuring CPT values.